Why is the Race Oncology share price soaring 13% today?

New trial results have excited ASX investors.

| More on:
A group of three scientists talking excitedly while working in a lab on a diabetes test developed by Proteomics International Laboratories which is an ASX share tipped to explode by Alto Capital

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • Race Oncology shares are soaring today on positive drug trial news
  • Cancer drug Zantrene was found to protect mice from chemotherapy damage 
  • Race Oncology said the results support future clinical trials 

The Race Oncology Ltd (ASX: RAC) share price is surging today on anti-cancer drug news.

Shares in the oncology company reached $2.10 in early trading, a 13% gain. For perspective, the S&P/ASX All Ordinaries Index (ASX: XJO) is 0.87% in the red today.

So, what scientific news did Race Oncology announce to the ASX today?

News of successful trial boosts Race Oncology share price

Investors appear to be buying up Race Oncology shares after the company released results from its latest trial.

The results showed that Race Oncology's anti-cancer drug Zantrene protected the hearts of mice from chemotherapy damage.

Their hearts were protected from the impact of anthracyclines when the chemotherapeutic dose of Zantrene was boosted. Anthacyclines are chemotherapy drugs commonly used to treat cancer.

No further toxicity or bone marrow suppression was identified with this higher dose.

Race Oncology is working with the University of Newcastle on this trial, as announced in April last year.

Race Oncology CEO Phillip Lynch said Zantrene is a "large commercial opportunity" with significant potential to improve modern chemotherapy.

He added: "We are committed to producing further preclinical data that will continue to prove the case for this opportunity for Zantrene."

The company said the results support further clinical trials using Zantrene with anthracyclines to improve cancer treatment.

Further commenting on the trial, associate professor Aaron Sverdlov said: "To date, there are no widely used or well established strategies to protect the heart against chemotherapy-induced damage."

Share price snapshot

Race Oncology shares have tumbled nearly 44% in the past year.

In the year to date alone, they have lost nearly 43%.

For perspective, the All Ords index has shed nearly 9% in a year.

Race Oncology has a market capitalisation of $329 million based on the current share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL share price leaping higher amid $1.9 billion funding news

ASX 200 investors are bidding up the CSL share price on Wednesday.

Read more »

Two happy scientists analysing test results.
Healthcare Shares

Mesoblast share price rockets 36% on breaking FDA news

ASX investors are sending the Mesoblast share price soaring following promising FDA news.

Read more »

a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.
Healthcare Shares

Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

Read more »

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Earnings Results

Chemist Warehouse merger target Sigma reports 149% FY24 profit jump

This could be the last set of results from Sigma as we know it if its merger is approved.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

1 ASX healthcare stock that looks severely undervalued

I think this stock looks too cheap to miss.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Own Medibank shares? Here's why it's a rewarding day for you

Shareholders are getting a healthy boost today.

Read more »

Health professional looking at a laptop.
Healthcare Shares

Are CSL shares a must-buy in March?

Let's see what analysts are saying about this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

This ASX healthcare stock is up 72% on FDA news and 'historic moment'

Huge gains are been recorded by this stock on Tuesday. But why?

Read more »